Assessment of Drug Adherence and Adverse Effects of Disease-Modifying Antirheumatic Drugs (DMARDs) in Patients of Rheumatoid Arthritis Attending a Tertiary Care Hospital in India

Tejal C. Patel, Prasad R. Pandit, Zankrut R. Doshi, Vikram A. Londhe

Abstract


Adherence to drug treatment is one of the key factors in treating chronic diseases like rheumatoid arthritis (RA) to maintain remission and prevent functional disability. Poor medication adherence is directly associated with a worse prognosis and an increase in healthcare utilization, adding to a financial burden. Hence, the present study was proposed to assess drug adherence in diagnosed patients of RA attending a tertiary care hospital. The study was initiated after obtaining institutional ethics committee permission, and written informed consent was requested from all the eligible patients before their enrolment. This cross-sectional questionnaire based study was conducted on RA patients attending the rheumatology outpatient department. The patient’s adherence to the drugs prescribed was assessed using the 19-item Compliance Questionnaire Rheumatology (CQR), and the correlation betweendrug adherencewithvariousdemographic,disease,andmedication-relatedvariableswasstudied. After screening 103 patients, 75 patients fulfilling the selection criteria were enrolled, and theirdatawasanalyzed. The adherence measured using the CQR score was in therange of 54.39% to 68.42%, with a mean CQR score of 62.27 ± 2.76.Anegative correlation was found between the CQR score and the number of ADRs (r=-0.12,p>0.05) and age (r=-0.06, p>0.05). A positive correlation was found between the CQR score and variables like sex, education, and number of medications, but none were statistically significant. Unsatisfactory compliance was evident in the present study. Therefore, integrating drug treatment with strategies to improve patient adherence may improve clinical outcomes and quality of life, reducing healthcare costs.

Keywords


Adherence; compliance questionnaire rheumatology; MMAS scale; compliance

Full Text:

PDF

References


Ankoor Shah, E. William St. Rheumatoid arthritis. In: Loscalzo J, Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal medicine. 21st Edition. New York:McGrow Hill; 2018. p.2751-65.

Sri Preethy NN, Churi S, Subramanian R, Joseph J, Tejaswini G, Rakshitha KR, et al. Study of health related quality of life in rheumatoid arthritis patients. Journal of Pharmacy Research.2015; 9(3):194-200.

Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia M, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Annals of the Rheumatic Diseases. 2019; 78(11):1463-71.

Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients’ lives. Clinical and Experimental Rheumatology. 2010; 28 (Suppl. 59):32- 40.

Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatology.1995;38(1):44-8.

Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care & Research (Hoboken). 2012; 64(5):640-47.

Drosos AA, Pelechas E, Voulgari PV. Rheumatoid Arthritis Treatment. A back to the drawing board project or high expectations for low unmet needs?. Journal of Clinical Medicine. 2019;8 (1237):1-6.

Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, St.Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis and Rheumatism. 2012; 64(9):2824-35.

Horne, RW.; Weinman, J.; Barber, N.; Elliott, RA.; Morgan, M. Concordance, Adherence and Compliance in Medicine Taking: A Conceptual Map and Research Priorities. National Co-coordinating Centre for NHS Service Delivery and Organization; London, UK: 2005.

Nakagawa S, Nakaishi M, Hashimoto M, Ito H, Yamamoto W, Nakashima R, et al. Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis. 2018 PLoS ONE 13(11): e0206943.

Marras C et al. Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study. Rheumatology International. 2017;

(7):1195-1202.

Bharthi P, Shobha V, Subramanya A. Patterns of drug use and factors affecting adherence to medication in patients with rheumatoid arthritis: A prospective, observational, hospital based study. International Journal Research Citation Index. 2019;7(1):OA1

Rauscher V, Englbrecht M, van der Heijde D, Schett G, Hueber AJ. High degree of nonadherence to disease- modifying antirheumatic drugs in patients with rheumatoid arthritis. Journal of Rheumatology. 2015;42(3):386-90.

Pasma A, van’t Spijker A, Hazes JMW, Busschbach JJV, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Seminars in Arthritis and Rheumatism. 2013; 43: 18-28.

Gadallah MA, Boulos DN, Gebrel A, Dewedar S, Morisky DE. Assessment of rheumatoid arthritis patients’ adherence to treatment. The American Journal of the Medical Sciences. 2015;349(2):151-6.

Marengo MF and María E Suarez-Almazor. Improving treatment adherence in patients with rheumatoid arthritis: what are the options?. International Journal of Clinical Rheumatology 2015; 10(5): 345-356.

Joplin S, van der Zwan R, Joshua F, Wong PK. Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. BioMed Research International. 2015;2015:150658.

Wabe N, LeeA,Wechalekar M, McWilliams L, Proudman S, Wiese M. Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients. International Journal of Clinical Practice. 2019;73(7):e13375.

Sharma S, Roshi, Tandon VR, Mahajan

A. A Study Evaluating Adherence and Compliance of Anti-rheumatic Drugs in Women Suffering from Rheumatoid Arthritis. Journal of Clinical and Diagnostic Research.2015;9(11): 1-4.

de Thurah A, Norgaard M, Johansen MB, Stengaard-Pedersen K. Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study. The Scandinavian Journal of Rheumatology. 2010;393:197–205.

de Klerk E, van der Heijde D, Landewe R, van der Tempel H, van der Linden S. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. Journal of Rheumatology. 2003;30(11):2469-75.

Salt E, Hall L, Peden AR, Home R. Psychometric properties of three medication adherence scales in patients with rheumatoid arthritis. Journal of Nursing Measurement. 2012; 20(1):59-72.

de Cuyper, E., De Gucht, V., Maes, S. et al. Determinants of methotrexate adherence in rheumatoid arthritis patients. Clinical Rheumatology.2016.35; 1335-39.

van den Bemt BJ, van den Hoogan FH, Bernard B, Hekster YA, van Riel PL, van Lankveld W. Adherence Rates and Associations with Non adherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs. The Journal of Rheumatology. 2009;36(10):2164-70.

Garcia -Gonzalez A, Richardson M, Garcia Popa -Lisseanu M, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clinical Rheumatology. 2008;27(7):883-889.

Fraenkel L et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Research (Hoboken). 2021;73(7):924-




DOI: https://doi.org/10.15416/pcpr.v8i3.39664

Refbacks

  • There are currently no refbacks.


                                                                         
Pharmacology and Clinical Pharmacy Research is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
 
                                                                      VIEW VISITOR STATS